Legato Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
Other funds holding SUPN
VPM
VCM
NAMI
AC
Legato Capital Management's SUPN Position: Q1 2026 in Review
Legato Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 3.5% in Q1 2026, selling an estimated $26.2K and leaving 14,108 shares worth $729K. The position accounts for 0.07% of the portfolio, ranked #392.
Legato Capital Management first reported a position in SUPN in Q4 2016 and has held it in 19 quarters since. The position peaked at $1.08M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Legato Capital Management held 14,108 shares of Supernus Pharmaceuticals worth $729K as of Q1 2026.
- Legato Capital Management sold 515 Supernus Pharmaceuticals shares in Q1 2026, an estimated $26.2K.
- Supernus Pharmaceuticals made up 0.07% of Legato Capital Management's portfolio in Q1 2026, its #392 holding.
- Legato Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
- Legato Capital Management's Supernus Pharmaceuticals position peaked at $1.08M in Q3 2025.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.